A recombinant bispecific single-chain fragment variable specific for HLA class II and FcαRI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells

Journal of Immunology

Volumn 184, Issue 3, 2010, Pages 1210-1217

  Guettinger, Yvonne ^a   Barbin, Karin ^a   Peipp, Matthias ^b   Bruenke, Joerg ^a   Dechant, Michael ^b   Horner, Heike ^a   Thierschmidt, Doreen ^a   Valerius, Thomas ^b   Repp, Roland ^c   Fey, Georg H ^a   Stockmeyer, Bernhard ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c Division of Hematology and Oncology   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; FC ALPHA RECEPTOR I; FC RECEPTOR; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G1; RECOMBINANT BISPECIFIC SINGLE CHAIN FRAGMENT VARIABLE; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; FC(ALPHA) RECEPTOR; HLA D ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN FV; LEUKOCYTE ANTIGEN;

ADULT; AGED; ANIMAL CELL; ANTIGEN BINDING; ARTICLE; B CELL LYMPHOMA; CELL ISOLATION; CHROMATOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; EFFECTOR CELL; FEMALE; GENE CONSTRUCT; HUMAN; HUMAN CELL; HYBRIDOMA; INSECT CELL; LYMPHOID CELL; LYMPHOMA CELL LINE; MACROPHAGE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PURIFICATION; SEQUENCE ANALYSIS; TARGET CELL; TUMOR CELL; ANIMAL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; B LYMPHOCYTE; CELL LINE; CELL MOTION; CHEMISTRY; DRUG ANTAGONISM; GENETICS; HAMSTER; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; PROTEIN BINDING; TUMOR CELL CULTURE; TUMOR CELL LINE;

ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD; B-LYMPHOCYTE SUBSETS; CELL LINE; CELL LINE, TUMOR; CELL MOVEMENT; CRICETINAE; HLA-D ANTIGENS; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOGLOBULIN VARIABLE REGION; LYMPHOMA, B-CELL; MICE; NEUTROPHILS; PROTEIN BINDING; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 77949327876     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0902033     Document Type: Article

References (42)

1. Carter, P. J. 2006. Potent antibody therapeutics by design. Nat. Rev. Immunol. 6: 343-357.
2. McLaughlin, P., A. J. Grillo-López, B. K. Link, R. Levy, M. S. Czuczman, M. E. Williams, M. R. Heyman, I. Bence-Bruckler, C. A. White, F. Cabanillas, et al. 1998. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16: 2825-2833.
3. Castillo, J., E. Winer, and P. Quesenberry. 2008. Newer monoclonal antibodies for hematological malignancies. Exp. Hematol. 36: 755-768.
4. Bargou, R., E. Leo, G. Zugmaier, M. Klinger, M. Goebeler, S. Knop, R. Noppeney, A. Viardot, G. Hess, M. Schuler, et al. 2008. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321: 974-977.
5. Link, B., H. Wang, J. Byrd, J. Leonard, T. Davis, W. Hall, J. Turner, G. Rodrigues, D. Levitt, G. Weiner, 2000. Phase I trial of humanized 1D10 (Hu1D10) monoclonal antibody targeting class II molecules in patients with relapsed lymphoma. Proc. Am. Soc. Clin. Oncol. 19: (Abstr. 86).
6. Stockmeyer, B., M. Schiller, R. Repp, H. M. Lorenz, J. R. Kalden, M. Gramatzki, and T. Valerius. 2002. Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10 - a humanized human leucocyte antigen DR antibody. Br. J. Haematol. 118: 959-967.
7. Nagy, Z. A., B. Hubner, C. Löhning, R. Rauchenberger, S. Reiffert, E. Thomassen-Wolf, S. Zahn, S. Leyer, E. M. Schier, A. Zahradnik, et al. 2002. Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells. Nat. Med. 8: 801-807.
8. Rech, J., R. Repp, D. Rech, B. Stockmeyer, M. Dechant, G. Niedobitek, M. Gramatzki, and T. Valerius. 2006. A humanized HLA-DR antibody (hu1D10, apolizumab) in combination with granulocyte colony-stimulating factor (filgrastim) for the treatment of non-Hodgkin's lymphoma: a pilot study. Leuk. Lymphoma 47: 2147-2154.
9. Dechant, M., J. Bruenke, and T. Valerius. 2003. HLA class II antibodies in the treatment of hematologic malignancies. Semin. Oncol. 30: 465-475.
10. Ghetie, V., and E. S. Ward. 2000. Multiple roles for the major histocompatibility complex class I- related receptor FcRn. Annu. Rev. Immunol. 18: 739-766.
11. Clynes, R. A., T. L. Towers, L. G. Presta, and J. V. Ravetch. 2000. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. 6: 443-446.
12. Nimmerjahn, F., and J. V. Ravetch. 2005. Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310: 1510-1512. (Pubitemid 41746349)
13. Weng, W. K., and R. Levy. 2003. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 21: 3940-3947.
14. Lin, T. S., I. W. Flinn, R. Modali, T. A. Lehman, J. Webb, S. Waymer, M. E. Moran, M. S. Lucas, S. S. Farag, and J. C. Byrd. 2005. FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia. Blood 105: 289-291.
15. Lejeune, J., G. Thibault, D. Ternant, G. Cartron, H. Watier, and M. Ohresser. 2008. Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies. J. Clin. Oncol. 26: 5489-5491; author reply 5491-5482.
16. Peipp, M., and T. Valerius. 2002. Bispecific antibodies targeting cancer cells. Biochem. Soc. Trans. 30: 507-511.
17. di Carlo, E., M. Iezzi, T. Pannellini, F. Zaccardi, A. Modesti, G. Forni, and P. Musiani. 2001. Neutrophils in anti-cancer immunological strategies: old players in new games. J. Hematother. Stem Cell Res. 10: 739-748.
18. Hernandez-Ilizaliturri, F. J., V. Jupudy, J. Ostberg, E. Oflazoglu, A. Huberman, E. Repasky, and M. S. Czuczman. 2003. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin. Cancer Res. 9: 5866-5873.
19. Repp, R., H. H. van Ojik, T. Valerius, G. Groenewegen, G. Wieland, C. Oetzel, B. Stockmeyer, W. Becker, M. Eisenhut, H. Steininger, et al. 2003. Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcgammaRI x anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer. Br. J. Cancer 89: 2234-2243.
20. Elsässer, D., T. Valerius, R. Repp, G. J.Weiner, Y. Deo, J. R. Kalden, J. G. van de Winkel, G. T. Stevenson, M. J. Glennie, and M. Gramatzki. 1996. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor. Blood 87: 3803-3812.
21. Mita, C. A., K. Papadopopoulos, M. M. Mita, A. Ricart, J. Sarantopopoulos, K. Berg, B. Uritz, E. Levy, I. Lowy, and A. W. Tolcher. 2006. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of MDX-214, a novel immune-mediated mechanism agent targeting the epithelial growth factor receptor (EGFR), in patients with advanced solid tumors. 2006 American Society of Clinical Oncology Annual Meeting Proceedings Part I. J. Clin. Oncol. 24 (June 20 Suppl.): 2523.
22. Stockmeyer, B., M. Dechant, M. van Egmond, A. L. Tutt, K. Sundarapandiyan, R. F. Graziano, R. Repp, J. R. Kalden, M. Gramatzki, M. J. Glennie, et al. 2000. Triggering Fc α-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy. J. Immunol. 165: 5954-5961.
23. Dechant, M., G. Vidarsson, B. Stockmeyer, R. Repp, M. J. Glennie, M. Gramatzki, J. G. van De Winkel, and T. Valerius. 2002. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing. Blood 100: 4574-4580. (Pubitemid 35429700)
24. Krebber, A., S.Bornhauser, J. Burmester, A. Honegger, J. Willuda, H. R. Bosshard, and A. Plückthun. 1997. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J. Immunol. Methods 201: 35-55. (Pubitemid 27072663)
25. Peipp, M., H. Küpers, D. Saul, B. Schlierf, J. Greil, S. J. Zunino, M. Gramatzki, and G. H. Fey. 2002. A recombinant CD7-specific single-chain immunotoxin is a potent inducer of apoptosis in acute leukemic T cells. Cancer Res. 62: 2848-2855. (Pubitemid 34525770)
26. Bruenke, J., B. Fischer, K. Barbin, K. Schreiter, Y. Wachter, K. Mahr, F. Titgemeyer, M. Niederweis, M. Peipp, S. J. Zunino, et al. 2004. A recombinant bispecific single-chain Fv antibody against HLA class II and FcgammaRIII (CD16) triggers effective lysis of lymphoma cells. Br. J. Haematol. 125: 167-179.
27. Stockmeyer, B., D. Elsässer, M. Dechant, R. Repp, M. Gramatzki, M. J. Glennie, J. G. van de Winkel, and T. Valerius. 2001. Mechanisms of G-CSF- or GM-CSFstimulated tumor cell killing by Fc receptor-directed bispecific antibodies. J. Immunol. Methods 248: 103-111. (Pubitemid 32167028)
28. Peipp, M., D. Saul, K. Barbin, J. Bruenke, S. J. Zunino, M. Niederweis, and G. H. Fey. 2004. Efficient eukaryotic expression of fluorescent scFv fusion proteins directed against CD antigens for FACS applications. J. Immunol. Methods 285: 265-280. (Pubitemid 38224567)
29. Tiroch, K., B. Stockmeyer, C. Frank, and T. Valerius. 2002. Intracellular domains of target antigens influence their capacity to trigger antibody-dependent cell-mediated cytotoxicity. J. Immunol. 168: 3275-3282. (Pubitemid 34250388)
30. Valerius, T., D. Elsässer, R. Repp, J. G. Van de Winkel, M. Gramatzki, and M. Glennie. 1997. HLA class II antibodies recruit G-CSF activated neutrophils for treatment of B cell malignancies. Leuk. Lymphoma 26: 261-269. (Pubitemid 27401909)
31. Dörrie, J., W. Schuh, A. Keil, E. Bongards, J. Greil, G. H. Fey, and S. J. Zunino. 1999. Regulation of CD95 expression and CD95-mediated cell death by interferon-γ in acute lymphoblastic leukemia with chromosomal translocation t(4; 11). Leukemia 13: 1539-1547. (Pubitemid 29465616)
32. Stockmeyer, B., T. Beyer, W. Neuhuber, R. Repp, J. R. Kalden, T. Valerius, and M. Herrmann. 2003. Polymorphonuclear granulocytes induce antibody-dependent apoptosis in human breast cancer cells. J. Immunol. 171: 5124-5129. (Pubitemid 37432795)
33. Blancheteau, V., D. Charron, and N. Mooney. 2002. HLA class II signals sensitize B lymphocytes to apoptosis via Fas/CD95 by increasing FADD recruitment to activated Fas and activation of caspases. Hum. Immunol. 63: 375-383.
34. Horner, H., C. Frank, C. Dechant, R. Repp, M. Glennie, M. Herrmann, and B. Stockmeyer. 2007. Intimate cell conjugate formation and exchange of membrane lipids precede apoptosis induction in target cells during antibody-dependent, granulocyte-mediated cytotoxicity. J. Immunol. 179: 337-345. (Pubitemid 46986550)
35. van Spriel, A. B., J. H. Leusen, M. van Egmond, H. B. Dijkman, K. J. Assmann, T. N. Mayadas, and J. G. van de Winkel. 2001. Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation. Blood 97: 2478-2486.
36. Kellner, C., J. Bruenke, J. Stieglmaier, M. Schwemmlein, M. Schwenkert, H. Singer, K. Mentz, M. Peipp, P. Lang, F. Oduncu, et al. 2008. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells. J. Immunother. 31: 871-884.
37. Wolf, E., R. Hofmeister, P. Kufer, B. Schlereth, and P. A. Baeuerle. 2005. BiTEs: bispecific antibody constructs with unique anti-tumor activity. Drug Discov. Today 10: 1237-1244. (Pubitemid 41411434)
38. Cartron, G., H. Watier, J. Golay, and P. Solal-Celigny. 2004. From the bench to the bedside: ways to improve rituximab efficacy. Blood 104: 2635-2642. (Pubitemid 39434941)
39. Wang, S., E. Racila, R. P. Taylor, and G. J. Weiner. 2006. NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement. Blood 111: 1456-1463. (Pubitemid 351213433)
40. Klepfish, A., A. Schattner, H. Ghoti, and E. A. Rachmilewitz. 2007. Addition of fresh frozen plasma as a source of complement to rituximab in advanced chronic lymphocytic leukaemia. Lancet Oncol. 8: 361-362. (Pubitemid 46464534)
41. Monteiro, R. C., and J. G. Van De Winkel. 2003. IgA Fc receptors. Annu. Rev. Immunol. 21: 177-204.
42. Lum, L. G. 1987. The kinetics of immune reconstitution after human marrow transplantation. Blood 69: 369-380. (Pubitemid 17022001)